Crcm LP Acquires 8,629,103 Shares of ALT5 Sigma Corporation $AIFC

Crcm LP raised its holdings in ALT5 Sigma Corporation (NASDAQ:AIFC) by 373.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,941,280 shares of the company’s stock after purchasing an additional 8,629,103 shares during the period. ALT5 Sigma comprises approximately 4.1% of Crcm LP’s holdings, making the stock its 6th largest holding. Crcm LP owned about 0.09% of ALT5 Sigma worth $12,035,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. UBS Group AG raised its position in shares of ALT5 Sigma by 179.3% in the 4th quarter. UBS Group AG now owns 1,904,567 shares of the company’s stock valued at $2,095,000 after purchasing an additional 1,222,690 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of ALT5 Sigma during the 3rd quarter valued at approximately $102,000. Private Advisor Group LLC acquired a new stake in shares of ALT5 Sigma during the 3rd quarter valued at approximately $61,000. Goldman Sachs Group Inc. raised its position in shares of ALT5 Sigma by 42.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 52,632 shares of the company’s stock valued at $58,000 after acquiring an additional 15,731 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of ALT5 Sigma during the 3rd quarter valued at approximately $45,000. 6.27% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Wall Street Zen lowered ALT5 Sigma from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 18th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

ALT5 Sigma Price Performance

Shares of AIFC opened at $0.66 on Friday. The stock has a fifty day moving average price of $0.89 and a 200 day moving average price of $1.33. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.82 and a current ratio of 0.82. ALT5 Sigma Corporation has a 12 month low of $0.63 and a 12 month high of $10.80.

ALT5 Sigma (NASDAQ:AIFC) last issued its quarterly earnings data on Monday, May 18th. The company reported ($2.14) EPS for the quarter. The company had revenue of $4.71 million for the quarter. ALT5 Sigma had a negative return on equity of 68.25% and a negative net margin of 2,483.94%.

ALT5 Sigma Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.